代谢性炎症新概念及其与非酒精性脂肪性肝病发病机制和治疗靶点的联系  

The pathogenesis and potential therapeutic targets of metaflammation in NAFLD

作　　者：牛春燕 黄健康 NIU Chunyan;HUANG Jiankang(Department of Digestive Diseases,Lishui People′s Hospital,Nanjing 211200,China)

机构地区：[1]南京市溧水区人民医院消化内科,南京211200 [2]南京市溧水区人民医院神经内科,南京211200

出　　处：《实用医学杂志》2024年第18期2525-2529,共5页The Journal of Practical Medicine

基　　金：江苏省“双创博士”计划项目(编号:JSSCBS-20211551);南京市卫生科技发展专项资金项目计划(编号:YKK22240)。

摘　　要：“代谢性炎症”由HOTAMISLIGIL于2006年提出,是一种由营养和能量过剩等代谢因素引起的慢性低度炎症,长期维持在亚急性水平。其中多种炎症细胞和免疫细胞浸润,多种炎症因子和免疫因子参与,炎症分子的表达或活性增强,引起炎症损伤。近年对代谢相关脂肪性肝病的深入研究发现,代谢性炎症在NAFLD的发病机制中起到关键作用,其中涉及的相关炎症通路为靶向药物的研发提供了广阔前景。本文综述了代谢性炎症在NAFLD中的最新进展。"Metaflammation,"proposed by Hotamisligil in 2006,refers to a chronic low-grade inflamma⁃tion triggered by metabolic factors such as excessive nutrition and energy,persisting at subacute levels over an extended period.Immune cells infiltrate the inflammatory site,leading to enhanced expression or activity of various inflammatory molecules and subsequent inflammatory damage.Recent research on metabolic-related fatty liver disease has revealed that modern metaflammation plays a pivotal role in the pathogenesis of NAFLD.The associated inflammatory pathways offer promising prospects for the development of targeted drugs.This article provides an updated review on the advancements in metaflammation within NAFLD.

关 键 词：代谢性炎症 非酒精性脂肪性肝病 炎症分子 炎症通路 靶向药物 

分 类 号：R575.5[医药卫生—消化系统] R453.9[医药卫生—内科学] R589.2[医药卫生—临床医学]